GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » Capex-to-Operating-Income

LungLife AI (LSE:LLAI) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LungLife AI Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

LungLife AI's Capital Expenditure for the six months ended in Dec. 2023 was £-0.06 Mil. Its Operating Income for the six months ended in Dec. 2023 was £-2.27 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


LungLife AI Capex-to-Operating-Income Historical Data

The historical data trend for LungLife AI's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI Capex-to-Operating-Income Chart

LungLife AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

LungLife AI Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LungLife AI's Capex-to-Operating-Income

For the Diagnostics & Research subindustry, LungLife AI's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LungLife AI's Capex-to-Operating-Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LungLife AI's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where LungLife AI's Capex-to-Operating-Income falls into.



LungLife AI Capex-to-Operating-Income Calculation

LungLife AI's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.061) / -4.565
=N/A

LungLife AI's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.057) / -2.267
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LungLife AI  (LSE:LLAI) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


LungLife AI Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of LungLife AI's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


LungLife AI (LSE:LLAI) Business Description

Traded in Other Exchanges
N/A
Address
2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320
LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines